Perceptive Advisors’s Adicet Bio ACET Stock Holding History

Perceptive Advisors’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-83	Closed	-$10K	–	127
2020 Q1	$10K	Hold	83	–	–	﹤0.01%	113
2019 Q4	$14K	Buy	+83	New	+$42K	﹤0.01%	113

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Perceptive Advisors's ACET Position: Q2 2020 in Review

Perceptive Advisors sold out of Adicet Bio (ACET) in Q2 2020, closing a stake of 83 shares — an estimated $10K sold.

Perceptive Advisors first reported a position in ACET in Q4 2019 and held it in 2 quarters. The position peaked at $14K in Q4 2019. 53 funds tracked by Wall St. Rank hold ACET as of Q2 2020.

Perceptive Advisors reported no remaining Adicet Bio position as of Q2 2020 after selling out during the quarter.
Perceptive Advisors sold 83 Adicet Bio shares in Q2 2020, an estimated $10K.
Perceptive Advisors first reported a position in Adicet Bio in Q4 2019 and held it in 2 quarters.
Perceptive Advisors's Adicet Bio position peaked at $14K in Q4 2019.
53 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2020.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.